1. Introduction {#sec1}
===============

Hypertriglyceridemia (HTG) is commonly encountered in the clinic \[[@bib1]\]. Of all adults, 27% have HTG (plasma triglycerides level\>2 mmol/L) \[[@bib2]\]. Increasing production of triglyceride-rich lipoproteins can lead to HTG, resulting in increasing the presence of the remnant particles in the circulation \[[@bib3]\]. Recently, a large-scale Mendelian randomization experiment provided compelling consistent evidences that triglycerides are in causal pathways for the development of coronary heart disease \[[@bib4]\]. Moreover, elevated triglyceride levels are considered as strong and independent predictors for atherosclerotic cardiovascular disease (ASCVD) and mortality \[[@bib5], [@bib6], [@bib7]\]. Despite improved ASCVD outcome with statin therapy, residual risk remains \[[@bib8], [@bib9], [@bib10]\], indicating that triglyceride-rich lipoproteins may be an important additional target for therapy. As expected, patients with elevated triglyceride levels, despite the use of statins, additionally received Icosapent Ethyl, one class of triglyceride-lowering drugs, which can significantly reduce the risk of ischemic events, including cardiovascular death \[[@bib11],[@bib12]\]. Thus, triglyceride-lowering therapy has gained renewed interest. Given important clinical relevance and therapeutic implications of HTG, clarification of molecular mechanism underlying HTG development and progression is critical to find potential drug targets of HTG.

Long noncoding RNAs (lncRNAs), no-protein-coding transcripts longer than 200 nucleotides (nt), are located within both the cytoplasm and the nucleus \[[@bib13], [@bib14], [@bib15]\]. Currently, with the development of high-throughput sequencing technology, a large number of lncRNAs have been found and thought to have a vital and wide range of biological functions \[[@bib16]\], including chromatin modification \[[@bib17]\], genomic imprinting \[[@bib18]\], and modulation of post-translational RNA processing \[[@bib19]\]. In recent years, despite the fact that many novel lncRNAs have been implicated in the pathogenesis of hepatocyte cholesterol metabolism \[[@bib20],[@bib21]\], systemic lipid homeostasis \[[@bib22]\], and high-fat diet-related obesity \[[@bib23],[@bib24]\], little is known about the biological function and significance of the potential molecular mechanism about lncRNAs in high-fat diet-induced HTG.

In the current study, in order to investigate the potential role of novel lncRNA in regulating the development of high-fat diet-induced HTG, we used transcriptome profiling to identify a novel lncRNA related to HTG in rats. Our study may provide new clues on the molecular events for potential therapeutic targets of HTG patients.

2. Methods {#sec2}
==========

2.1. Animal models {#sec2.1}
------------------

All experimental procedures involving the use of animals were conducted in accordance with the National Institutes of Health (NIH) and ARRIVE Guidelines for the welfare of animals, and the operation on the laboratory animals was approved by the Animal Care and Use Committee of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China). A total of 24 healthy male Sprague--Dawley rats weighing in around 200 g were obtained from the Animal Development Center (Chinese Academy of Sciences, Shanghai). All rats were acclimated for 1 week before the initiation of the experiment and maintained on a 12/12 h light/dark cycle with free access to food and water. Rats were randomly divided into two groups (n = 12 each): control group (normal diet (ND) group) that received regular rodent chow diet (59.6% carbohydrate, 8.5% fat, and 20.3% protein in total calories) and high-fat diet (HFD) group that were fed with a high-fat diet (43% carbohydrate, 41% fat, and 17% protein in total calories) for 24 weeks. To control the cost of the experiment, three rats were randomly selected from the control group and five rats with higher lipid profiles from the HFD group for subsequent transcriptome sequencing.

2.2. BRL-3A cell line and transient transfections {#sec2.2}
-------------------------------------------------

The BRL-3A rat liver cell line and HEK293T human renal epithelial cell lines (American Type Culture Collection) were cultured in glucose Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Carlsbad, CA, USA) at 37 °C with humidified air and 5% CO~2~. All of siRNAs and plasmids were transfected into cells applying Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA) according to the manufacturer\'s protocol. siRNAs were purchased from Riobio Co., Ltd. (Guangzhou, China).

2.3. RNA extraction and transcriptome sequencing {#sec2.3}
------------------------------------------------

The total RNA was extracted from each individual sample using RNAiso Plus Total RNA extraction reagent (Takara Biotechnology, Dalian, China) following the manufacturer\'s protocols. The purity and quantity of total RNA were determined by using the NanoDrop ND-2000 (Thermo Fisher, Wilmington, DE, USA). The integrity of RNA was assessed by Agilent 2100 Bioanalyzer system with an RNA 6000 Nano Assay Kit (Agilent Technologies, Santa Clara, CA, USA) as instructed. RNA was further purified by using the RNeasy Micro Kit and RNase-Free DNase set according to the manufacturer\'s recommendations (QIAGEN, GmBH, Germany).

Initially, a total amount of 3 μg RNA per sample was used as a genetic material for the RNA sample preparations. Ribosomal RNA was removed by using the Ribo-Zero rRNA Removal Kit (Epicenter, USA), and ribosomal RNA-free residue was cleaned up by using ethanol precipitation. Sequencing libraries were generated using TruSeq RNA Sample Preparation Kit v2 (Illumina, San Diego, CA, USA) following the manufacturer\'s instructions. Subsequently, the products of libraries were purified using AMPure XP system (Beckman Coulter, Beverly, CA, USA). Finally, the quantity and quality of each library were assessed by Qubit® 2.0 Fluorimeter (Invitrogen Life Technologies, Carlsbad, USA) and Agilent 2100 Bioanalyzer system (Agilent Technologies, Santa Clara, CA, USA), respectively. All the sequencing libraries\' construction and transcriptome sequencing were performed at the Shanghai Biotechnology Corporation (Shanghai, China) on an Illumina Hissed 2500 platform (Illumina, San Diego, CA, USA) according to the Selex transcriptome sequencing protocols. All of the RNA transcriptome sequencing data have been uploaded to the GEO database.

2.4. Quantitative real-time PCR validation {#sec2.4}
------------------------------------------

The total RNA was extracted from rats\' liver tissues using TRIZOL reagent (Life Technologies, Carlsbad, CA) and then the 1ug of total RNA was converted to cDNA in 20 μL of reverse transcriptase reaction with PrimeScript™ RT Reagent Kit with gDNA Eraser (Takara Biotechnology, Dalian, China) according to the manufacturer\'s instructions. Real-time PCR was performed with the SYBR Green (Takara Biotechnology, Dalian, China) detected by a 7900HT FAST Real-Time PCR System (Life Technologies, Carlsbad, CA, USA). For quantitative analysis, the relative expression level of lncRNA or mRNA was normalized to an internal invariant control, U6 small nucleolar RNA, or GAPDH. Each reaction was performed in triplicate, and the expression of each lncRNA or mRNA was represented as fold change by using the 2-▵▵CT method. Primers used in the present study were listed in [Supplementary Table 2](#appsec1){ref-type="sec"}.

2.5. Northern Blot {#sec2.5}
------------------

Total RNAs were extracted from BRL-3A cells, and agarose gel electrophoresis was applied to censor the quality of total RNAs at the same time. Then, we identified the expression of *lnc19959.2* through Northern Blot with DIG Northern Starter Kit (Roche, USA). To prepare the probes by PCR for *lnc19959.2*, formaldehyde was used to denature gel electrophoresis overnight and transfer it to the nylon membrane (NC). Prehybridization of cross-linked membranes was performed with DIG Easy Hyb, and *lnc19959.2* expression was detected with probes (F: 5′ TACCTCAGATACTCAGCCACA 3′, R: 5′ GCAGGGTGCAGACTTCC 3'). Finally the Negative Control (NC) membrane was washed and the signal was detected and exposed in the darkroom with X-ray film using a Digoxin Hybridization Test Kit II (Roche, USA).

2.6. RACE {#sec2.6}
---------

Rapid amplification of cDNA ends (RACE) assays were rapid amplification of cDNA fragments from low-abundance transcripts to obtain a full-length cDNA with 5′ and 3′ ends. PCR experiments were performed with SMARTer RACE cDNA Amplification Kit (Clontech, USA) according to the manufacturer\'s protocol. The PCR products were detected by agarose gel electrophoresis and sequenced by Sanger Sequencing. The 5′ and 3′ RACE Gene Special Primers (GSPs) were listed in [Supplementary Table 3](#appsec1){ref-type="sec"}.

2.7. RNA pulldown assays {#sec2.7}
------------------------

RNA pulldown assays were performed with Pierce Magnetic RNA-Protein Pull-Down Kit (Thermo Fisher Scientific, USA) according to the manufacturer\'s protocol. Sense and antisense transcript of NONRATT019959.5 was labeled by Biotin RNA Labeling Mix (Roche Diagnostics, USA). RNA was incubated with DNase I at 37 °C, for 15 min, mixed with cell lysates at 4 °C for 1 h in rotation, and then 30 μL magnetic beads were added (Thermo Fisher Scientific, USA) combined with proteins. Complexes were detected by mass spectrometry and confirmed by western blot. The primers sequence was listed in [Supplementary Table 5](#appsec1){ref-type="sec"} and the proteins pulled down by *lnc19959.2* were listed in [Supplementary Table 6](#appsec1){ref-type="sec"}.

2.8. RIP {#sec2.8}
--------

RNA immunoprecipitation (RIP) assays were conducted using the Magan RIP^TM^RNA--Binding Protein Immunoprecipitation Kit (Millipore, USA). Anti-*Purb*, Anti-*hnRNPA2B1* (Abcam, Hong Kong, China), and Anti-IgG (Abnova Corporation, Taiwan, China) were immunoprecipitated with lysed cell extracts according to the manufacturer\'s protocol. Immunoprecipitated RNA was quantified by RT-qPCR. Each reaction was performed in triplicate.

2.9. ChIP {#sec2.9}
---------

Chromatin immunoprecipitation (ChIP) assays were conducted with ChIP Assay Kit (Beyotime Institute of Biotechnology, Nanjing, China) according to the manufacturer\'s protocol. We fixed cells using paraformaldehyde to crosslink chromatin DNA and sonicated it to 200--800 bp fragments. Anti-*Purb*, anti-*Cebpb*, anti-RNA polymerase II (RNP II), and anti-*hnRNPA2B1* (Abcam Hong Kong, China) and anti-IgG (Abnova Corporation, Taiwan, China) were used to immunoprecipitate DNA. The primer sequence was listed in [Supplementary Table 7](#appsec1){ref-type="sec"}.

2.10. Quantification and statistical analysis {#sec2.10}
---------------------------------------------

All data were presented as mean ± standard error of the mean (SEM). Significance was assessed by one-way ANOVA followed by Tukey\'s test and LSD for multiple comparisons. A Chi-square test was used to assess the significance of variables in the contingency table. The correct *P* values for these multiple tests were calculated by false discovery rate (FDR), unless otherwise indicated. All the statistics were performed in SPSS 22.0 (SPSS Inc., Chicago, Illinois, USA) for Windows (Microsoft Corp, Redmond, Washington, USA). A *P* value \< 0.05 was considered statistically significant. All probability values were 2-sided.

2.11. Data and software availability {#sec2.11}
------------------------------------

### 2.11.1. Accession number {#sec2.11.1}

The accession number for the microarray published here is GEO: [GSE137712](ncbi-geo:GSE137712){#intref0010}, [GSE99557](ncbi-geo:GSE99557){#intref0015}, and [GSE137131](ncbi-geo:GSE137131){#intref0020}. All informatics analysis was performed by using the R language platform, a well-known open-source software environment for statistical computing and graphics.

3. Results {#sec3}
==========

3.1. lncRNA *lnc19959.2* was upregulated during hepatocyte triglyceride metabolism *in vivo* and *in vitro* {#sec3.1}
-----------------------------------------------------------------------------------------------------------

In an attempt to discover the functional lncRNAs associated with hepatocyte triglyceride metabolism *in vivo*, we performed RNA-seq analysis of ribosomal RNA-depleted total RNA in liver tissues from Sprague--Dawley (SD) rats fed with or without HFD ([Figure 1](#fig1){ref-type="fig"}A,B and [Supplementary Figs. 1A--1C](#appsec1){ref-type="sec"}; ND (n = 3) versus HFD (n = 5), ∼1 mmol/L versus ∼3.5 mmol/L), a widely used animal model for hypertriglyceridemia. Global lncRNA profile analysis revealed that 832 out of 31244 lncRNAs were significantly differentially expressed ([Figure 1](#fig1){ref-type="fig"}C). Among these differentially expressed lncRNAs, 68 lncRNAs were downregulated and 73 lncRNAs were upregulated (*P* \< 0.05; fold change\>2.0, [Figure 1](#fig1){ref-type="fig"}D). An upregulated and uncharacterized lncRNA, termed *lnc19959.2* (gene symbol *NONRATT019959.2*), was successfully validated by RT-qPCR and further confirmed the upregulation in BRL-3A rat liver cell lines by stimulating with palmitic acid (PA) ([Figure 1](#fig1){ref-type="fig"}E) which was especially upregulated TG level ([Supplementary Figs. 1D and 1E](#appsec1){ref-type="sec"}). Given that relevancy of *lnc19959.2* in hepatocyte triglycerides metabolism *in vitro* and *in vivo*, it was chosen for subsequent functional study.Figure 1**Lnc19959.2 is a novel lncRNA highly expressed in rat fatty livers.** (A) Schematic diagram shows rat livers (ND, n = 3; HFD, n = 5) selected for RNA-seq. (B) Serum total triglyceride (TG) levels in normal diet (ND) and high-fat diet (HFD) rats. Serum TG was significantly increased after 8 weeks in HFD rats. (C) Heatmap of 832 different expression lncRNAs (ND, n = 3; HFD, n = 5). (D) The number of significantly changed lncRNAs (red indicates the upregulated lncRNAs, with fold change \> 2.0; green indicates the downregulated lncRNAs, with fold change\<0.5). (E) RT-qPCR analysis the lncRNA expressions after treating BRL-3A cells with palmitate acid (300 μM) for 24 h. The CT value of GAPDH was 13.483 ± 1.192 (n = 3) and lnc19959.2 was 21.791 ± 0.171 (n = 3, mean ± SD). Unpaired *t*-test was used to measure the statistical significance; ∗*P* \< 0.05, ∗∗*P* \< 0.01, ∗∗∗*P* \< 0.001, and ∗∗∗∗*P* \< 0.0001. Results are mean ± SEM of three independent experiments with duplicate wells.Figure 1

3.2. Identification and characterization of *lnc19959.2* as a long-chain noncoding RNA {#sec3.2}
--------------------------------------------------------------------------------------

Initially, northern blot with overlap probe detected two transcripts ([Supplementary Fig. 2A](#appsec1){ref-type="sec"}): one transcript for *Slc35c2* (1859 nt less than 2027 nt) and the other transcript for *lnc19959.2* (more than 2332 nt), respectively. To further identify the exact sequence and full length of *lnc19959.2*, we applied the SMART RACE technology to get its 3′ and 5' end sequences ([Supplementary Figs. 2B and 2C](#appsec1){ref-type="sec"}) and found that the total length of *lnc19959.2* transcript was 2501 nt ([Supplementary Fig. 2D](#appsec1){ref-type="sec"}). Subsequently, using a BLAST search of the *lnc19959.2* sequence retrieved from the NONCODE database, we identified that this lncRNA was located on a modestly conserved locus chromosome 12.3q ([Supplementary Figs. 2E and 2F](#appsec1){ref-type="sec"}) and partially overlapped with *Slc35c2* gene exons 8, 9, and 10. Like other lncRNAs, *lnc19959.2* was transcribed with a polyA + tail ([Supplementary Fig. 2G](#appsec1){ref-type="sec"}) but was without coding capacity ([Supplementary Fig. 2K](#appsec1){ref-type="sec"}--2L). *Lnc19959.2* was mainly located in the nucleus but not the cytoplasmic region, which is different from the *Slc35c2* gene ([Supplementary Fig. 2H](#appsec1){ref-type="sec"}). The analysis of the expression of *lnc19959.2* in different rat major tissues revealed that it was widely distributed and showed no more tissue-restricted expression patterns ([Supplementary Figs. 2I and 2J](#appsec1){ref-type="sec"}).

3.3. Knockdown of *lnc19959.2* has profound TG lowering effects *in vitro* and *in vivo* {#sec3.3}
----------------------------------------------------------------------------------------

To explore the functional role of *lnc19959.2* in the regulation of hepatocyte lipid metabolism *in vitro* ([Supplementary Fig. 3A](#appsec1){ref-type="sec"}), we tested and identified a smart silence RNA that could specifically suppress the expression of *lnc19959.2* but not *Slc35c2* gene for more than 80% ([Figure 2](#fig2){ref-type="fig"}A). Remarkably, the knockdown of *lnc19959.2* decreased triglycerides but not cholesterol levels along with PA physiological simulation in BRL-3A cells ([Figure 2](#fig2){ref-type="fig"}B,C). Consistent with this interpretation, we observed that fewer lipid droplets accumulate in the *lnc19959.2* knockdown status ([Figure 2](#fig2){ref-type="fig"}D,E). By contrast, similar results cannot be found in the *Slc35c2* knockdown status ([Supplementary Figs. 3D and 3E](#appsec1){ref-type="sec"}).Figure 2**Knockdown lnc19959.2 reduces plasma TG levels in rats**. (A) RT-qPCR analysis lnc19959.2 expression level following transient transfection of BRL-3A cells with smart siRNA of lnc19959.2. (B--C) The TC and TG levels detected in BRL-3A cells after transient transfection siRNA of lnc19959.2 with or without PA. (D--E) Oil Red O-hematoxylin staining of BRL-3A cells after transient transfection siRNA of lnc19959.2 with PA. (F) Plasma TG levels in high-fat diet (HFD) rats of control (GFP, n = 6) and lnc19959.2 KD (KD-lnc19959.2, n = 9) after a 6-hour fast (Fast 6 h), a 24-hour fast (Fast 24 h), or 12-hour refeeding after a 24-hour fast (Refeed 12 h). (G) Blood triglyceride levels detected at different time points (0, 0.5, 1, 2, and 3 h) after receiving olive oil by oral gavage in ND rats which are injected with adenovirus and, for another group, after receiving olive oil and 0.9% sodium chloride, separately (∗*P* \< 0.05 means 0.9% sodium chloride versus olive oil, and *P* \< 0.05 means GFP versus KD-lnc19959.2). Unpaired *t*-test was used to measure the statistical significance; ∗*P* \< 0.05, ∗∗*P* \< 0.01, ∗∗∗*P* \< 0.001, and ∗∗∗∗*P* \< 0.0001.Figure 2

We further assess the impact of the knockdown of *lnc19959.2* in the regulation of TG metabolism *in vivo* by using different rat models. As expected, efficiently knockdown of *lnc19959.2* with adenovirus dramatically reduced serum TG levels in all three feeding conditions ([Figure 2](#fig2){ref-type="fig"}F and [Supplementary Figs. 3F--3H](#appsec1){ref-type="sec"}). In addition, we observed that the knockdown of *lnc19959.2* showed a marginal increase in their circulating TG that quickly returned to baseline in 3 h of lipid load assay with orally delivering a dose of olive oil ([Figure 2](#fig2){ref-type="fig"}G) in the ND rat model. To determine whether *lnc19959.2* is a novel candidate therapeutic target lncRNA for improving the conditions of hypertriglyceridemia, we administrated *lnc19959.2* knockdown adenoviruses into a high-fat-fed rat with hypertriglyceridemia. Plasma TG level was significantly reduced by 30%∼50% but not in the TC level on the *lnc19959.2* knockdown rats.

3.4. *Lnc19959.2* is required to maintain the expression of TG-Associated genes {#sec3.4}
-------------------------------------------------------------------------------

To better decipher the contributions of *lnc19959.2* to hepatocyte triglyceride metabolism, a global gene expression profiling analysis was performed in *lnc19959.2*-silenced BRL-3A rat liver cell lines ([Figure 3](#fig3){ref-type="fig"}A and [Supplementary Fig. 4A](#appsec1){ref-type="sec"}). Initially, gene ontology analysis differentially expressed genes showed enrichment in lipid, especially in triglyceride metabolic processes ([Figure 3](#fig3){ref-type="fig"}B,C and [Supplementary Fig. 4C](#appsec1){ref-type="sec"}). Subsequently, we used RT-qPCR analysis to confirm that these genes from the gene ontology (GO) pathways were regulated partially. It is noteworthy that *ApoA4* was statistically downregulated, while *Cpt1a*, *Tm7sf2*, and *Gpam* were upregulated in the *lnc19959.2*-silenced BRL-3A cell line ([Figure 3](#fig3){ref-type="fig"}D).Figure 3**lnc19959.2 participates in many metabolism pathways and affects a series of TG-associated genes.** (A) Heatmap of mRNA expression profile sequence, after knockdown of lnc19959.2 expressions in BRL-3A cells. (B) Gene ontology analysis of microarray in BRL-3A cell treatment of siRNA of lnc19959.2 and Negative Control (NC). (C) The top 30 KEGG pathways correlated with the cellular process, environmental information processing, genetic information processing, human diseases, metabolism, and organismal systems. (D) RT-qPCR detected a subset of the lipid-related pathway gene expressions.Figure 3

3.5. Identification of *Purb* and *hnRNPA2B1* as binding partners of *lnc19959.2* {#sec3.5}
---------------------------------------------------------------------------------

We next sought to determine the underlying molecular mechanism by which *lnc19959.2* regulates triglycerides-associated genes. Owing to *lnc19959.2* mainly present in the nucleus without the evidence of translation ability, we proposed that *lnc19959.2* acts as a nuclear RNA. Because the knockdown *lnc19959.*2 had no effect on the expression of adjacent protein-coding genes ([Supplementary Figs. 5A and 5B](#appsec1){ref-type="sec"}), we excluded the possibility that *lnc19959.2* acts by influencing its adjacent genes in *cis-*regulation.

As some nuclear lncRNAs have been shown to affect transcription by physical interaction with intracellular protein \[[@bib25], [@bib26], [@bib27]\], we next conducted RNA pulldown assays to capture potential interacting proteins. As shown in the flow diagram ([Figure 4](#fig4){ref-type="fig"}A), sense and antisense of *lnc19959.2* were labeled with biotin, and then the captured and eluted proteins were determined by mass spectrometry (MS) ([Figure 4](#fig4){ref-type="fig"}B). Interestingly, Purb and hnRNPA2B1, two nuclear-localized proteins, were identified as binding partners of *lnc19959.2* ([Figure 4](#fig4){ref-type="fig"}C). Subsequently, RIP assays further confirmed the specificity of these interactions ([Figure 4](#fig4){ref-type="fig"}D). RNA folding analysis identified a stable stem-loop structure within the 3′ region of *lnc19959.2*, indicating the necessary spatial conformation for the interaction ([Figure 4](#fig4){ref-type="fig"}E). In addition, we also predicted the protein-RNA interaction signals between 3′ and 5' regions of *lnc19959.2* with Purb and hnRNPA2B1, respectively ([Supplementary Fig. 5C](#appsec1){ref-type="sec"}). To further explore that the definite region genuinely interacts with *lnc19959.2*, we analyzed a series of truncated sequences and found that most of the 3′ fragment and a small portion of the 5′ fragment of *lnc19959.2* are involved in the interaction with Purb and hnRNPA2B1 ([Figure 4](#fig4){ref-type="fig"}F).Figure 4**lnc19959.2 interacts with Purb and hnRNPA2B1.** (A) Experimental design for RNA pulldown assay to identify the cellular proteins associating with lnc19959.2. lnc19959.2 was transcription-labeled with biotin *in vitro*, refolded, and incubated with BRL-3A total cell lysates. (B) Venn diagram showing the number of different proteins binding with lnc19959.2_sense and lnc19959.2_antisense, separately, according to the MS analysis. And 10 proteins were overlapped. (C) Four of the candidate proteins filtered from mass spectrometry. Purb and hnRNPA2B1 were confirmed that they were specifically bound to lnc19959.2. (D) RIP assay analysis of Purb and hnRNPA2B1 associated with lnc19959.2. BRL-3A cell lysates were immunoprecipitated with anti-*Purb* and anti-*hnRNPA2B1* or control mouse IgG antibody. RT-qPCR was used to validate the presence of lnc19959.2 in the complexes. (E) The total length of lnc19959.2 minimum free energy (MFE) secondary structure. This structure is colored by base-pairing probabilities. And red shows high confidence and blue is just the opposite. (F) The different length (full-length (FL) and truncated lnc19959.2 (Δ1: 1--650, Δ2: 1--1300, Δ3: 1--1950, FL: 1--2501, Δ4: 651--1300, Δ5: 1301--1950, Δ6: 1951--2501)) of lnc19959.2 were biotinylated in RNA pulldown assays and western blot was used to detect Purb and hnRNPA2B1. Unpaired *t*-test was used to measure the statistical significance; ∗∗∗∗*P* \< 0.0001.Figure 4

3.6. *Lnc19959.2* upregulates ApoA4 expression via ubiquitinated transcription inhibitor factor Purb {#sec3.6}
----------------------------------------------------------------------------------------------------

Owing to the fact that *Purb* is a transcription inhibitor factor, we hypothesized that lnc19959.2 modulates the expression of TG-associated genes via Purb protein. Notably, knocked down *Purb* increased while the overexpression of *Purb* decreased ApoA4 expression ([Figure 5](#fig5){ref-type="fig"}A and [Supplementary Figs. 6B and 6C](#appsec1){ref-type="sec"}). To further determinate the mechanism by which *Purb* regulated *ApoA4* expression, we performed sequence analysis and identified that five PNRs (*Purb* binding sites) were located at −2.0 kb of *ApoA4* promoter, respectively ([Supplementary Fig. 6A](#appsec1){ref-type="sec"}). Of them, PNR at −2000∼-1500 bp is most conserved in rats, mice, and humans ([Figure 5](#fig5){ref-type="fig"}C). Notably, much higher basal and *Purb* inhibited luciferase activities were observed on Luc-*ApoA4*-2000 ([Figure 5](#fig5){ref-type="fig"}B), indicating that the suppressed promoter and *Purb* responsive elements are within this region. Moreover, the inhibitory efficiency showed a dose-dependent manner with the increment of *Purb* ([Figure 5](#fig5){ref-type="fig"}D). In contrast, when we deleted 11 bp nucleotides including *Purb* site at −2000∼-1500 bp from Luc-*ApoA4*-2000, the promoter lost both basal, and *Purb* inhibited activities ([Figure 5](#fig5){ref-type="fig"}E). To determine whether Purb proteins bound to the *ApoA4* promoter in intact cells, we applied chromatin immunoprecipitation (ChIP) assay and detected Purb binding to the −2000∼-1500 bp regions of the *ApoA4* promoter in BRL-3A cells ([Figure 5](#fig5){ref-type="fig"}F).Figure 5**Purb acts as a transcriptional repressor to inhibit ApoA4 expression.** (A) Western blot detected the ApoA4 and Purb expression levels after knockdown or overexpression of Purb in BRL-3A cells. (B) Dual-luciferase reporter assay detected relative luciferase activities after cotransfection of four truncated ApoA4 promoters with pcDNA3.1 vector or pc3.1-*Purb* in HEK293T cells. (C) The schematic diagram shows that *Purb* binding site (PNR) contained at 2000 bp of ApoA4 promoter was well conserved. (D) Dual-luciferase reporter assay detected relative luciferase activities after cotransfection of ApoA4 promoters of 2000 bp with pcDNA3.1 vector or pc3.1-*Purb* in different doses (range: 0--1.5 μg/mL) in HEK293T cells. (E) Dual-luciferase reporter assay detected relative luciferase activities after cotransfected with wt/mutApoA4 promoters of 2000 bp with pc3.1-*Purb* in HEK293T cells. (F) ChIP analysis of Purb interaction with the ApoA4 promoter. BRL-3A cells lysates were immunoprecipitated with anti-*Purb* or control mouse IgG antibody. (G--H) Overexpression of lnc19959.2 and control in BRL-3A cells, respectively, were incubated with the proteasome inhibitor MG-132 (10 μM) or the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) for 6 or 12 h. The protein level of Purb extracted from the whole cell was detected by western blot. (I--J) BRL-3A cells lysates were immunoprecipitated with an HA or Flag-specific antibody in BRL-3A cell lysates which were stably expressing ubiquitin with C-terminal HA tag or Purb with C-terminal Flag tag, respectively. And then they were analyzed by western blot with anti-*Purb* or anti-Ubiquitin. Bottom, the input of the cell lysates. (K) Western blot detects the ubiquitination levels in BRL-3A cells. Unpaired *t*-test was used to measure the statistical significance; ∗*P* \< 0.05, ∗∗*P* \< 0.01, and ∗∗∗*P* \< 0.001.Figure 5

Next, we want to explore the molecular consequences of the interaction between *lnc19959.2* and *Purb*. Overexpression of *lnc19959.2* dramatically diminished the level of Purb protein. Reciprocally, the knockdown of *lnc19959.2* increased the level of Purb protein ([Supplementary Fig. 6F](#appsec1){ref-type="sec"}). However, we did not observe a reduction in *Purb* transcription level ([Supplementary Fig. 6D](#appsec1){ref-type="sec"}). To further determine the mechanism by which *lnc19959.2* reduced Purb protein stability, we treated *lnc19959.2* overexpressing and control BRL-3A cells with the protein synthesis inhibitor cycloheximide (CHX) or the proteasome inhibitor MG-132. As shown in [Figure 5](#fig5){ref-type="fig"}G,H, only MG-132 abolished the downregulation of Purb protein level in BRL-3A cells when overexpressing *lnc19959.2*. Indicating *lnc19959.2* may downregulate Purb protein abundance via the ubiquitin-proteasome pathway ([Supplementary Fig. 6G](#appsec1){ref-type="sec"}). To further confirm our study, we conducted the immunoprecipitation assays to detect whether Purb and ubiquitin interacted with each other ([Figure 5](#fig5){ref-type="fig"}I,J and [Supplementary Figs. 6H and 6I](#appsec1){ref-type="sec"}). Indeed, the overexpression of *lnc19959.2* dramatically ubiquitinated Purb protein in BRL-3A cells ([Figure 5](#fig5){ref-type="fig"}K).

3.7. *Lnc19959.2* interacts with *hnRNPA2B1* to downregulate *Cpt1a*, *Tm7sf2,* and *Gpam* expressions {#sec3.7}
------------------------------------------------------------------------------------------------------

To further explore the function of the interaction between *hnRNPA2B1* and *lnc19959.2*, we examined the regulatory effects of *hnRNPA2B1* on the expression of *lnc19959.2* target genes in BRL-3A cells. After the siRNA-mediated knockdown of *hnRNPA2B1*, we observed significant changes in many metabolism pathways ([Figure 6](#fig6){ref-type="fig"}A,B). In addition to preferentially binding RNA, hnRNPA2B1 also specifically binds with multiple promoter DNA sequences and acts as a regulatory factor, thereby participating in the regulation of transcription \[[@bib28]\]. Thus, we hypothesize that *hnRNPA2B1* may perform this function at *lnc19959.2* target gene locus. In support of this idea, the overexpression of *lnc19959.2* in BRL-3A cells remarkably reduced the *hnRNPA2B1* engagement in promoters of its target genes, including *Cpt1a*, *Tm7sf2*, and *Gpam* ([Figure 6](#fig6){ref-type="fig"}C). Given that *lnc19959.2* was a nuclear lncRNA, we also tested its ability to affect RNA polymerase II-dependent transcription. Similar results could be found in the RNA polymerase II (RNPII) engagement in the setting of *lnc19959.2* expressions ([Figure 6](#fig6){ref-type="fig"}D). In addition, Cpt1a, Tm7sf2, and Gpam protein expression levels were reduced particularly in the *lnc19959.2* overexpression panel ([Figure 6](#fig6){ref-type="fig"}E). Based on these findings, we proposed a model that *lnc19959.2* reduced the occupancy of hnRNPA2B1 along with RNA polymerase II in the promoter of its target genes, which result in inactivation of these gene expressions.Figure 6***Cpt1a*, *Tm7sf2*, and *Gpam* are coregulatory by lnc19959.2-*hnRNPA2B1*.** (A--B) The top 30 gene ontology (GO) related to biological process (BP), cellular component (CC), and molecular function (MF) and the top 30 KEGG pathways correlated with the cellular process, environmental information processing, genetic information processing, human diseases, metabolism, and organismal systems in *hnRNPA2B1* knockdown BRL-3A cells. (C) ChIP-qPCR analysis recruitment of hnRNPA2B1 to promoter regions determined in BRL-3A cells transduced with control (pcDNA3.1) or lnc19959.2 overexpression (pc3.1-lnc19959.2). The results retrieved and normalized by an upstream site (region 1) are shown as a percent of input (n = 3 per group). (D) ChIP-qPCR analysis recruitment of RNA polymerase II (RNPII) to promoter regions determined in BRL-3A cells transduced with control (pcDNA3.1) or lnc19959.2 overexpressing plasmid (pc3.1-lnc19959.2). Results retrieved and normalized by an upstream site (region1) are shown as a percent of input (n = 3 per group). (E) Western blot detected Cpt1a, Tm7sf2, and Gpam protein expression levels. Unpaired *t*-test was used to measure the statistical significance; ∗∗*P* \< 0.01.Figure 6

3.8. *Lnc19959.2* is activated by the transcription factor of CCAAT/Enhancer-Binding Protein Beta (*Cebpb*) under palmitate acid stimulation {#sec3.8}
--------------------------------------------------------------------------------------------------------------------------------------------

To elucidate the mechanism by which *lnc19959.2* was upregulated in HFD-rat livers, we investigated the transcription factors (TFs) that had a response for the expression of *lnc19959.2* in the BRL-3A cell line with the treatment of PA. Sequence analysis revealed a number of TFs within the *lnc19959.2* promoter region ([Supplementary Fig. 7A](#appsec1){ref-type="sec"}). A series of RT-qPCR was used to identify the dramatic changes of these TF expressions with the treatment of PA ([Figure 7](#fig7){ref-type="fig"}A). Remarkably, *Cebpb*, which acts as a classical transcription factor involved in several cellular processes and in various diseases, appeared more frequently in website predictions ([Supplementary Fig. 7B](#appsec1){ref-type="sec"}). Thus, we assumed that *Cebpb* was most likely a transcriptional activator of *lnc19959.2*.Figure 7**Cebpb activates the lnc19959.2 expression.** (A) Heatmaps present gene expressions selected from sequence prediction software. (B--C) RT-qPCR analysis of lnc19959.2 expression levels in BRL-3A cells in the condition of knockdown or overexpression of Cebpb. (D) Dual-luciferase reporter assay detected relative luciferase activities after cotransfection of four truncated lnc19959.2 promoters with pcDNA3.1 vector or pc3.1-Cebpb in HEK293T cells. (E) Dual-luciferase reporter assay detected relative luciferase activities after cotransfection of lnc19959.2 promoters of 1500 bp with pcDNA3.1vector or pc3.1-Cebpb in different doses (range: 0--1.5 μg/mL) in HEK293T cells. (F) Schematic diagram shows that the part of lnc19959.2 promoter sequence of wt and mut of Cebpb binding site is located in −1500～-1000 bp. (G) Dual-luciferase reporter assay detected relative luciferase activities after being cotransfected with wt/mutlnc19959.2 promoters of 1500 bp with pc3.1-Cebpb in HEK293T cells. (H) ChIP analysis of Cebpb interacted with the lnc19959.2 promoter. BRL-3A cells lysates were immunoprecipitated with anti-Cebpb or control mouse IgG antibody. Unpaired *t*-test was used to measure the statistical significance; ∗∗*P* \< 0.01, ∗∗∗*P* \< 0.001, and ∗∗∗∗*P* \< 0.0001.Figure 7

As expected, the expression of *lnc19959.2* was downregulated or upregulated by interfering with or overexpressing *Cebpb* in BRL-3A cell lines, respectively ([Figure 7](#fig7){ref-type="fig"}B,C). Furthermore, dual luciferase assay showed that the transcriptional activity of *lnc19959.2* was activated after cotransfecting with *Cebpb* expressing plasmids ([Figure 7](#fig7){ref-type="fig"}D). Activation of *lnc19959.2* promoters was most evident in the −1500 bp region, and the relative fluorescence activity showed a dose-dependent increase when the *Cebpb* plasmid concentration increased ([Figure 7](#fig7){ref-type="fig"}E). In contrast, the luciferase activity was significantly attenuated when we mutated the *Cebpb* binding site of *lnc19959.2* upstream sequence ([Figure 7](#fig7){ref-type="fig"}F,G). Finally, ChIP assays confirmed that *Cebpb* actually bound to the promoter region of *lnc19959.2* ([Figure 7](#fig7){ref-type="fig"}H). In addition, the *LXRα* agonist T0901317 first activated *Cebpb* and subsequently upregulated the *lnc19959.2* expression ([Supplementary Figs. 7C and 7D](#appsec1){ref-type="sec"}).

4. Discussion {#sec4}
=============

Here, we proposed the functional actions of *lnc19959.2* in modulating triglycerides metabolism, as shown in the graphical abstract. In hepatic cells, the transcriptional factor *Cebpb* was initially activated when exposed to high lipid condition; after that, it directly bound to the promoter of *lnc19959.2* and then promoted its expression. *lnc19959.2* was mainly located in the nucleus; it specifically bound to Purb and hnRNPA2B1. Intriguingly, it acted in a distinctively different manner on modulating TG metabolism-associated gene expressions when they interacted with these two nuclear proteins. On the one hand, *lnc19959.2*-mediated ubiquitination increased the degradation of Purb protein, a transcriptional repressor, and in turn attenuated its binding to the promoter of *ApoA4* gene, resulting in an increased expression of *ApoA4*; on the other hand, *lnc19959.2* interacted with *hnRNPA2B1*, a transcriptional coactivator, and cooperated with RNA polymerase II that controls the basal and inducible expression of *Cpt1a*, *Tm7sf2*, and *Gpam*. All in all, we outlined *lnc19959.2*, induced by high lipid condition, participated in modulating the TG association gene expression, and causally linked to hyperlipidemia. Our work demonstrated a new layer regulatory complexity of an lncRNA that modulates triglyceride metabolism and also broadens the known mechanisms of lncRNA actions.

Recently, a genome-wide association study and subsequent resequencing study have successfully identified genetic variants within the *APOA5/APOA4/APOC3/APOA1* cluster associated with TG levels \[[@bib29],[@bib30]\]. Despite microRNAs \[[@bib31],[@bib32]\], a number of lncRNAs, such as *APOA1-*AS and *APOA4-*AS within these well-known gene clusters, participated in TG regulation \[[@bib33],[@bib34]\]. Of important note, *APOA4-*AS is coexpressed with *APOA4* and concordantly and specifically regulates the expression of *APOA4*, which is well known to have important roles in enhancing hepatic TG secretion and increasing plasma TG levels \[[@bib35]\]. In contrast to *APOA4-*AS that acts as in *cis*-regulation, *lnc19959.2* acts as *decoy* mode in *trans* to upregulate the *ApoA4* expression and finally participates in TG metabolism. Conversely, several key genes known to regulate TG metabolism were also downregulated by *lnc19959.2*, including *Cpt1a*, *Gpam*, and *Tm7sf2*. *Cpt1a* is reported to be involved in long-chain fatty acid and triglyceride metabolic process \[[@bib36]\], while *Gpam* and *Tm7sf2* can regulate *SREBP* and are involved in lipid and lipoprotein metabolism \[[@bib37], [@bib38], [@bib39]\]. Given that these target mRNAs mentioned above are majorly involved in TG metabolism, it is not surprising that dysregulation of *lnc19959.2* level could be related to TG metabolism.

*HnRNPA2B1* belongs to the A/B subfamily of ubiquitously expressed heterogeneous nuclear ribonucleic proteins (hnRNPs) \[[@bib28]\]. It acts as an RNA binding protein and plays very important roles in multiple aspects of RNA metabolism \[[@bib40]\], including transcription \[[@bib28]\], alternative splicing \[[@bib41]\], mRNA stability \[[@bib41]\], and mRNA degradation \[[@bib42]\]. In the present study, we performed RNA-seq in which *hnRNPA2B1* knockdown samples showed significant enrichment in lipid metabolic processes. In addition, Kyoto Encyclopedia of Genes and Genomes (KEGG) classification related to genes includes lipid and energy metabolism pathways. In accordance with the established roles in lipid metabolism, the knockdown of *hnRNPA2B1* regulated the expression of *Cyp7a1* and *Abca1* in hepatocyte cholesterol metabolism as mentioned in previous reports \[[@bib20]\]. Intriguingly, *hnRNPA2B1* showed the ability to modulate the target gene expression in distinctive manners, such as inactive transcription in TG metabolism (our study), and to promote RNA degradation in cholesterol metabolism as previously described \[[@bib20]\]. Moreover, another hnRNP, named *RALY*, is mediated by *LeXis* and acts as a transcriptional cofactor for cholesterol biosynthetic genes in the mouse liver \[[@bib21]\]. These results support the notion that an lncRNA-hnRNP-target gene axis is operational in rats/mice and may have relevance in [dyslipidemia](http://www.baidu.com/link?url=zg6IrzNaXKrVU-0d4nEV2gScK3Xf1Sp1HcHWwgO2SIQmrSdBVW3bDq2EIQ_QcGpH1fHZ9fVTj1gaqx79sVvgFgVLcBKRAnwc85MLgM8mDWC){#intref0025}. Therefore, it will be interesting to identify additional novel lncRNAs that interacted with hnRNP to regulate its target genes and ultimately coordinate other lipids metabolism in the future.

The current study has several important limitations which should be acknowledged. Firstly, it was worthy noticing that there was no clear evidence that *lnc19959.*2 has conserved RNA transcript in human beings. Thus, further studies in humans are needed to explore this in future. Secondly, *lnc19959.2* was located in both the nucleus and cytoplasm, indicating that it controls triglyceride metabolism on multiple levels. Although our present study demonstrated that *lnc19959.2* works as a functional nuclear transcript, we cannot exclude a possibility that it is also regulated through cytosolic events, which warrant further study. Thirdly, one potential pitfall of our study is that it is very difficult to model the genuine liver biology role of *lnc19959.2* in the regulation of hepatocyte TG metabolism by using hepatic cell lines, and in the future, this may be further explored in a transgenic rat model. However, the successful replication of effect on TG regulation in two rat live cell lines (BRL-3A and CBRH-7919) and subsequent hub gene expression signals (*ApoA4*, *Cpt1a*, *Tm7sf2*, and *Gpam*) and the interactions among Purb and hnRNPA2B1 with *lnc19959.2* were additionally tested and confirmed in the high-fat fed rat liver model by using *lnc19959.2* knockdown adenoviruses *in vivo* that improves the plausibility of our study ([Supplementary Fig. 8](#appsec1){ref-type="sec"}).

In summary, our work revealed the noncoding RNA *lnc19959.2* as an additional mediator of the complex effects on hepatic TG metabolism. These data demonstrated that *lnc19959.2* contributes to the ability similar to PA to promote TG metabolism. The findings of the present study also suggest that the inhibition of *lnc19959.2* elicits a lipid lowering effect in the high lipid environment that may contribute to a potential therapeutic benefit in the future.
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